IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Condense Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Mime-Version:
1.0
Sender:
Information and Referral and Internet Sightings <[log in to unmask]>
Subject:
generic neurontin (gabapentin)
From:
Sylvia Caras <[log in to unmask]>
Date:
Mon, 7 Jun 2010 08:56:49 -0700
Message-ID:
<[log in to unmask]>
Content-Type:
text/plain; charset="us-ascii"; format=flowed
Reply-To:
[log in to unmask]
Parts/Attachments:
text/plain (12 lines) 
 From the PharmaLive.com News Archive - Jun. 04, 2010

Mylan today announced that its subsidiary Matrix Laboratories Limited 
has received final approval from the FDA for its ANDA for Gabapentin 
Tablets USP, 600 mg and 800 mg, the generic version of Pfizer's 
Neurontin Tablets for the treatment of postherpetic neuralgia, a 
complication of shingles. The product will be distributed by Mylan 
Pharmaceuticals. Gabapentin Tablets had U.S. sales of approximately 
$174 million for the 12 months ending March 31, 2010.

www.peoplewho.org

ATOM RSS1 RSS2